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Safety of magnetic resonance imaging of patients with a new
Medtronic EnRhythm MRI SureScan pacing system: clinical
study design
Abstract
Background Magnetic Resonance Imaging (MRI) of patients with implanted cardiac devices is currently
considered hazardous due to potential for electromagnetic interference to the patient and pacemaker
system. With approximately 60 million MRI scans performed worldwide per year, an estimated majority
of pacemaker patients may develop an indication for an MRI during the lifetime of their pacemakers,
suggesting that safe use of pacemakers in the MRI environment would be clinically valuable. A new
pacing system (Medtronic EnRhythm MRI TM SurescanTM and CapSureFix MRI TM leads) has been
designed and pre-clinically tested for safe use in the MRI environment. The EnRhythm MRI study is
designed to confirm the safety and efficacy of this new pacing system. Methods The EnRhythm MRI
study is a prospective, randomized controlled, unblinded clinical trial to confirm the safety and efficacy
of MRI at 1.5 Tesla in patients implanted with a specifically designed pacemaker and lead system. The
patients have standard indications for dual chamber pacemaker implantation. Successfully implanted
patients are randomized in a 2:1 ratio to undergo MRI (MRI group) or to have no MRI scan (control
group) at 9-12 weeks after pacemaker system implantation. Magnetic resonance (MR) scanning includes
14 head and lumbar scan sequences representing clinically relevant scans while maximizing the gradient
slew rate up to 200 T/m/s, and/or the transmitted radiofrequency (RF) power up to SAR (specific
absorption rate) levels of 2 W/kg body weight (upper limit of normal operating mode). Full interrogation
of all device information and sensing and capture function are measured at device implantation, every
follow-up and before and immediately after MRI in the MRI group and at the same time points in the
control group. Complete pacemaker and lead evaluations are also done at one week and one month after
the scan for the MRI and control group patients. The primary endpoint is safe and successful completion
of the MRI scan as measured by freedom from both MRI-procedure related complications and clinically
significant changes in the sensing and capture function of the leads. Results will be communicated after
approximately 156 and 470 patients have completed 4 months of follow-up. Trial Registration:
ClinicalTrials.gov identifier: NCT00433654. 
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Abstract
Background: Magnetic Resonance Imaging (MRI) of patients with implanted cardiac devices is
currently considered hazardous due to potential for electromagnetic interference to the patient
and pacemaker system. With approximately 60 million MRI scans performed worldwide per year,
an estimated majority of pacemaker patients may develop an indication for an MRI during the
lifetime of their pacemakers, suggesting that safe use of pacemakers in the MRI environment would
be clinically valuable. A new pacing system (Medtronic EnRhythm MRI™ SureScan™ and
CapSureFix MRI™ leads) has been designed and pre-clinically tested for safe use in the MRI
environment. The EnRhythm MRI study is designed to confirm the safety and efficacy of this new
pacing system.
Methods: The EnRhythm MRI study is a prospective, randomized controlled, unblinded clinical
trial to confirm the safety and efficacy of MRI at 1.5 Tesla in patients implanted with a specifically
designed pacemaker and lead system. The patients have standard indications for dual chamber
pacemaker implantation. Successfully implanted patients are randomized in a 2:1 ratio to undergo
MRI (MRI group) or to have no MRI scan (control group) at 9–12 weeks after pacemaker system
implantation. Magnetic resonance (MR) scanning includes 14 head and lumbar scan sequences
representing clinically relevant scans while maximizing the gradient slew rate up to 200 T/m/s, and/
or the transmitted radiofrequency (RF) power up to SAR (specific absorption rate) levels of 2 W/
kg body weight (upper limit of normal operating mode). Full interrogation of all device information
and sensing and capture function are measured at device implantation, every follow-up and before
and immediately after MRI in the MRI group and at the same time points in the control group.
Complete pacemaker and lead evaluations are also done at one week and one month after the scan
for the MRI and control group patients.
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Trials 2008, 9:68 http://www.trialsjournal.com/content/9/1/68The primary endpoint is safe and successful completion of the MRI scan as measured by freedom
from both MRI-procedure related complications and clinically significant changes in the sensing and
capture function of the leads.
Results: Results will be communicated after approximately 156 and 470 patients have completed
4 months of follow-up.
Trial Registration: ClinicalTrials.gov identifier: NCT00433654.
Background
Magnetic Resonance Imaging (MRI) of patients with pace-
makers and other implanted devices is presently contrain-
dicated, because of the potential hazards of this diagnostic
method on active implants [1]. However, there is an
increased need for MRI in these and other older patients
[2]. With approximately 60 million MRI scans performed
worldwide per year, an estimated majority of pacemaker
patients may be indicated for an MRI during the lifetime
of their pacemaker, suggesting that safe use of pacemakers
in an MRI environment would be clinically valuable.
Several studies report that a small number of pacemaker
patients underwent MRI scanning under controlled situa-
tions and by taking certain precautions. This was only
done if the risk-benefit ratio was considered acceptable.
Still, scanning pacemaker patients in an MRI is not with-
out risk. Six non pacemaker-dependent patients died in
Germany during an MRI examination that took place
without any monitoring. In three of these cases, there was
suggestive evidence that death may have been due to
induced ventricular fibrillation [3]. Other studies have
shown that pacing thresholds increased significantly from
pre- to post-MRI examination [4,5]. Furthermore, animal
testing has demonstrated that the temperature at the lead
tip increased up to 20°C during MRI scanning of the heart
[6], which could result in tissue damage.
Pacemaker systems can be designed to limit the potential
risks of MRI for patients. Such a design has been realised,
prompting a clinical trial to test its function with and
without MRI. Since all available pacemaker systems are
currently contraindicated for use during MRI, the new
pacing system consisting of the EnRhythm MRI™ SureS-
can™ pacemaker and CapSureFix MRI™ Model 5086 leads
are evaluated for safe use in the MRI environment. This
pacing system is a modified version of the commercially
available EnRhythm® pacemaker and CapSureFix® Novus
Model 5076 leads. The design of the study evaluating this
pacemaker system is reported in this paper.
Pacemaker design enhancements were made to minimize
the energy induced on leads and discharged at electrodes.
Hardware changes were made to ensure reliable operation
while MRI is active. Leads were altered to reduce lead tip
heating from radiofrequency (RF). Radiopaque labels are
present on the lead and device to indicate that a system is
implanted that can be used in the MRI. Furthermore, the
pacemaker can be programmed to the MRI SureScan
mode to permit appropriate function during MRI scan-
ning. In this mode, the physician can choose either to pro-
gramme an asynchronous pacing mode or a non-pacing
mode. Asynchronous pacing will maintain appropriate
pacing support throughout the MRI examination regard-
less of the noise induced on the pacing system. For those
patients that are non-pacemaker dependent, the non-pac-
ing mode is available. Diagnostic data collection, auto-
matic system monitoring measurements, atrial
arrhythmia detection and atrial arrhythmia therapy are
suspended during MRI SureScan mode operation. Fur-
thermore, before programming the MRI mode, the system
reinforces the physician to check carefully the safety
requirements necessary for the pacemaker patient to
receive an MRI examination.
Study design
This study is a prospective, randomized controlled,
unblinded, multi-center investigational trial and is being
conducted in approximately 75 centers in the United
States (US), Canada, Europe and Middle East. After
implantation of the Medtronic EnRhythm MRI SureScan
system (Medtronic EnRhythm MRI™ SureScan™ pace-
maker and Medtronic CapSureFix MRI™ leads), patients
are required to have follow-up visits at 2 months, 2.5
months (between 9–12 weeks post-implant an MRI scan
or no-MRI scan is performed, depending on randomiza-
tion), 3 months (1 week post- MRI/no-MRI) and 4
months post-implant (1 month post-MRI scan/no-MRI).
Further follow-up is required at 6 months post-implant
and every 6 months thereafter until the study ends. Full
interrogation of all device information and impedance,
sensing and capture function are measured at implant,
every follow-up and immediately before and after MRI in
the MRI group and at the same time points in the control
group. The system must be implanted for more than 6
weeks to allow the Implantable Pulse Generator (IPG)
and leads to develop stable pacing and sensing function in
the patient prior to allowing the patient to undergo an
MRI scan.Page 2 of 8
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the effect of MRI on capture and sensing measurements is
unclear. The observed effect in this study will theoretically
result from the sum of the natural variation in capture and
sensing parameters common to all patients, added to the
effect of the MRI examination. Without a randomized
control group, it is impossible to isolate the effect of the
MRI from the component common to all patients with an
IPG system. The possible difference in the electrical meas-
urements due to the MRI scan is precisely what study
investigators wish to understand.
Inclusion/exclusion criteria
The following in-/exclusion criteria are used. Criteria were
primarily chosen to comply with the labeling of the pace-
maker system.
Inclusion Criteria
• Patients who have a Class I or II indication for implan-
tation of a dual chamber pacemaker according to the
American College of Cardiology (ACC)/American Heart
Association (AHA)/Heart Rhythm Society (HRS) guide-
lines [7].
• Patients must be able to undergo pectoral implantation.
• Patients who are able and willing to undergo elective
MRI scanning without sedation (anxiolysis permitted).
• Patients who are geographically stable and available for
follow-up at the study center for the length of the study.
Exclusion Criteria
• Patients who require a legally authorized representative
to obtain consent.
• Patients with a mechanical tricuspid heart valve
• Patients with tricuspid valve disease including valve
replacement.
• Patients for whom a single dose of 1.0 mg Dexametha-
sone acetate may be contraindicated.
• Patients who have a previously implanted pacemaker or
an implanted cardioverter/defibrillator. Those who have
abandoned pacemaker/ICD leads are excluded; however,
patients with complete system explantation may be
included.
• Patients who require an ICD rather than a pacemaker.
• Patients currently indicated, or for whom an indication
is anticipated, to undergo another MRI procedure other
than those specifically described in the study during the
period of follow-up required by the study.
• Patients with previously implanted active medical
devices (other than those stated above).
• Patients with non-MRI compatible devices (those above
and others such as neurostimulators) or implanted mate-
rial (e.g. non-MRI compatible sternal wires, biostimula-
tors, metals or alloys).
• Patients with medical conditions that preclude the test-
ing required by the protocol or limit study participation.
• Patients who are enrolled in or intend to participate in
another clinical trial (of an investigational drug or device,
new indication for an approved drug or device, or require-
ment of additional testing beyond standard clinical prac-
tice) during this clinical trial.
• Pregnant women, or women of childbearing potential
and who are not on a reliable form of birth control.
• Patients with exclusion criteria required by local law (e.g
age, breast feeding).
Pacemaker implantation and measurements
The devices to be implanted are the model 5086 MRI Cap-
SureFix® active fixation leads for both right atrium and
right ventricle. Typically right or left pectoral approaches
via the subclavian, axillary or cephalic veins are used to
introduce the leads, which are then advanced to the inves-
tigators' choice of location in the heart to sense and cap-
ture the atrial and ventricular myocardium. The
EnRhythm MRI SureScan IPG is connected to the leads in
the pectoral site.
After implantation, measurements of voltage stimulation
thresholds at 0.2 and 0.5 ms pulse duration, impedance
and sensing amplitudes measurements are taken in both
the atrium and ventricle. The investigator completes a
questionnaire concerning handling characteristics of the
leads during implantation.
Measurements at the time of MR scanning are described
below. Further sets of measurements of pacemaker func-
tion are made at every required follow-up visit.
Randomization
Patients were originally planned to be randomized in a
1:1 ratio, but later during the trial the ratio was modified
to a 2:1 ratio to undergo an MRI scan (MRI group) or not
to undergo an MRI scan (control group) after a successful
implantation of an EnRhythm MRI SureScan pacing sys-
tem (Figure 1). It is anticipated that more than 60% of thePage 3 of 8
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the remainder in a 2:1 order. The ratio was adjusted so as
to meet regulatory requirements for the minimum
number of patients scanned.
MRI scanning
Patients randomized to receive MR scanning undergo
imaging at 9–12 weeks after implantation. Fourteen clini-
cally relevant brain and lumbar spine MR scans are per-
formed in each patient of the MRI group (total MRI
investigation time of approximately 45 minutes, total
active MRI scan time of approximately 30 minutes).
According to the labelling of the MRI SureScan Pacing sys-
tem, all MRI studies are performed at a 1.5 Tesla system,
the slew rate ("gradient dB/dt") of the gradient system of
each individual MR sequence is restricted to 200 T/m/s
and the radiofrequency exposure of each individual MR
sequence is restricted to a specific absorption rate (SAR) of
2 W/kg body weight or less. Furthermore, labelling
requires that the isocenter of the RF coil falls above the
first cervical vertebral body (C1) or below the twelfth tho-
racic vertebral body (T12). The sequences to be used were
carefully chosen by the study's Scan Advisory Committee
to be clinically applicable and similar between different
commercially available 1.5 T closed bore MRI scanners
(manufacturers GE, Siemens, Philips) and to include
sequences utilizing high gradient slew rates and/or pro-
ducing high SAR close to the labelling limits of the pace-
maker system. Some of the MR scan protocols with
already high gradient slew rates were modified to maxi-
mize the gradient exposure up to the system limit or if
possible to 200 T/m/s. In addition, to maximize gradient
exposure in the lumbar spine scans, the patient is placed
in such a way (i.e., isocenter of the RF coil is at L1 and S1)
that the highest induced voltages at the pacing system site
are expected. At least one lumbar spine scan should
achieve high SAR values. Validation of all scans is required
by each center prior to executing the first study patient
scan in order to ensure scan protocols for each particular
site are comparable across sites.
At minimum, patients are continuously monitored via
pulse oximetry during the scans. Verbal communication
also takes place to assess or confirm any significant clini-
cal changes. Voltage stimulation thresholds, sensing
amplitudes and impedance, will be measured in both the
Study visit flowchartFigure 1
Study visit flowchart.Page 4 of 8
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scans are started and immediately after the MRI scans are
completed.
Although the clinical study includes a fixed set of brain
and lumbar spine sequences, the MRI scanning require-
ments of the EnRhythm MRI pacing system makes it pos-
sible to perform diagnostic MRI scans of the anatomic
region within C1 and T12 while placing the isocenter of
the RF coil outside of this zone by changing certain MRI
parameters.
Objectives of the study
Two sets of objectives will be analyzed. The first will be
analyzed after approximately 156 patients have been
implanted with this new pacemaker system and followed
for 4 months to provide data for Medtronic market release
outside of the US and the second analysis is after approx-
imately 470 patients have been implanted and are fol-
lowed for 4 months after receiving this new pacemaker
system for regulatory requirements purposes.
The first set of objectives related to the 156 patients
implanted and followed-up is described below:
a) Primary Objectives
1. To assess if the pacing system-, MRI- and implantation
procedure related complication rate from implantation
until one month post-MRI is greater than 80%. A one-
sided exact test with a 95% confidence interval is used for
analysis.
An adverse event (AE) is pacing system-related if it results
from the presence or performance of the system under
investigation. An AE or adverse device effect is MRI-proce-
dure related if it is caused by the interaction between the
investigational pacing system and the MRI system that
occurs during the MRI procedure and includes the time
the patient is within the 5 Gauss line of the MRI system
through the subject's 4 months follow-up (1 month post
MRI). In addition, AEs occurring due to the subject's MRI
programming will be considered MRI procedure-related.
An AE is implant-procedure related if it occurs due to the
implant procedure. An AE is classified as a complication if
it results in invasive intervention or the termination of sig-
nificant device function regardless of other treatments.
Intravenous and intramuscular drug therapies are consid-
ered invasive treatments.
2. To compare the changes in atrial and ventricular voltage
stimulation thresholds at 0.5 ms, before and one month
after MRI/no-MRI, between the MRI and control groups.
Changes in threshold are used to indicate potential myo-
cardial thermal damage. The hypothesis will test whether
the changes are statistically equivalent (Δ = 1 V) between
both groups. A two-sided confidence interval will be used
for analysis.
3. To compare the differences in atrial and ventricular
sensing amplitudes one month after MRI/no-MRI
between the MRI and control groups, making a statistical
comparison of the effect of MRI on these parameters. The
hypothesis will test whether the sense amplitudes are sta-
tistically equivalent (Δ = 1.7 mV atrium, 5.0 mV ventricle).
A two-sided confidence interval will be used for analysis.
All 3 primary objectives need to be met in order to pass
this first analysis of the study.
b) Secondary Objectives
All secondary objectives and additional analyses are ana-
lyzed using descriptive statistics but are not statistically
evaluated.
1. Confirm that labelling instructions for completing the
MRI scans were followed to ensure patient safety. Occur-
rence of system-related adverse device effects due to insuf-
ficiencies of the labelling or inadequacies of the labelling
are used.
2. Characterize occurrence of sustained ventricular
arrhythmias and asystole seen during MRI scans.
3. Characterize all implant procedure-, pacing system- and
MRI procedure-related complications and observations to
four months post-implant.
4. Summarize atrial and ventricular lead impedance up to
four months post-implant.
5. Characterize the lead handling of the CapSureFix MRI
lead model 5086 MRI in relation to the commercially
available model 5076. A seven-point questionnaire is
used.
6. Characterize four months pacing threshold and sense
amplitude of the MRI group and control group in relation
to the commercially available lead Model 5076.
c) Additional Analysis
1. Demonstrate that the EnRhythm MRI SureScan Pacing
System (both generator and leads) can be identified as
MRI-labelled with X-ray (Figure 2). A seven-point ques-
tionnaire is used.
The second analysis after 470 patients have been
implanted and followed-up for four months contains the
following objectives:Page 5 of 8
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1. To assess if the MRI-related complication-free rate in
the month following MRI is greater than 90%. A one-
sided exact test with a 97.5% confidence interval is used
for analysis.
2. To compare the changes in a) atrial and b) ventricular
voltage thresholds at 0.5 ms before and one month after
MRI/no-MRI between the MRI and control groups. The
hypothesis will test whether the proportions of patients
(p1and p2) that experience an acceptable threshold
increase less or equal to 0.5 V are equivalent (Δ = 10%, p1
and p2 = 96%) between the two groups. The objective will
be analyzed using a two-sample 97.5% confidence inter-
val, with p-values from the Farrington-Manning test for
equivalence of proportions.
3. To compare the changes in a) atrial and b) ventricular
sense amplitudes before and one month after MRI/no-
MRI between the MRI and control groups. The hypothesis
will test whether the proportions of patients (p1 and p2)
who experience a sense amplitude decrease less than 50%
and whose sense amplitudes remain above an clinically
acceptable minimum (1.5 mV for atrium and 5 mV for the
ventricle) at one month post-MRI/no-MRI are equivalent
(Δ = 10%, p1 and p2 = 93%) between the two groups. The
objective will be analyzed using a two-sample 97.5% con-
fidence interval, with p-values from the Farrington-Man-
ning test for equivalence of proportions.
All 3 primary objectives of this second set need to be met
in order to pass the study.
b) Secondary Objectives
In addition to the six secondary objectives listed above for
the first analysis, a further objective will characterize all
system-related complications between the implant proce-
dure and the four month follow-up visit to confirm that
the complication-free rate is greater than 80%. The objec-
tive is analyzed using a one-sided exact test with a 95%
confidence interval.
The secondary objectives for system-related complica-
tions, lead handling, and lead performance are evaluated
under the "fixed-sequence method" in order to preserve
the overall type one error of these objectives for regulatory
purposes. The three objectives are tested sequentially with
formal statistical tests. Lead handling is analyzed using a
95% confidence interval to assess whether the differences
in overall lead handling characteristics are statistically
equivalent between the EnRhythm MRI cohort and the
5076 historical comparison group (Δ = 1.5 units). Lead
performance is analyzed using 95% confidence intervals
to analyze whether the differences in capture and sensing
are statistically equivalent between the EnRhythm MRI
cohort and the 5076 historical comparison group (Δ = 0.5
V for capture, 0.9 mV for atrial sensing, and 2.5 mV for
ventricular sensing).
c) Additional analyses
In addition to the additional analysis listed above for the
first analysis, a further analysis will summarize aberrant or
undesirable behaviour of the MRI SureScan programming
mode, for which information is collected pertaining to its
use and performance.
Furthermore, a summary of whether safeguards and pro-
cedures were followed at the time of MRI scans will be
provided. Information is collected pertaining to whether
safeguards and procedures for the preparation, program-
ming, and monitoring around the time of the MRI scans
were followed for the cardiology and radiology teams.
Sample size and data use for analysis
Sample size calculations for both sets of objectives
exclude attrition and provide at least 80% power with a
type one error rate (alpha) of 0.05 (first set) or 0.025 (sec-
ond set). No alpha adjustment was necessary for the two
analyses, since the objectives are different and both sets
will each be analyzed only once. Sample sizes were calcu-
lated separately for each primary objective and the largest
requirements (62 patients per group for the first set, 122
per group for the second set) were further increased to 156
and 470 total patients, respectively, for consideration of
estimated study attrition and added regulatory require-
ments.
Radiopaque labels on lead and IPG to identify that patient has an MRI-conditional system implantedFigure 2
Radiopaque labels on lead and IPG to identify that patient has 
an MRI-conditional system implanted.Page 6 of 8
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investigational plan and include the following:
• Data from visits outside the 1 month post-MRI visit win-
dow are excluded from the primary analyses of capture
and sensing objectives, but are included in a secondary
sensitivity analysis of these objectives.
• Data from patients whose MRI scans were not per-
formed according to protocol requirements are excluded
from the analyses of capture, sensing, MRI-related compli-
cations, labeling instructions, occurrence of arrhythmias,
and lead impedance.
• Data from patients in atrial arrhythmias at the time of
electrical data collection are excluded from analyses of
atrial capture and sensing objectives at affected visits.
• Data from patients with unresolved lead dislodgments
are excluded from analyses of capture, sensing, and
impedance objectives.
• Data from patients with a pacing threshold difference
exceeding 0.5 V prior to the MRI visit, which is indicative
of an abnormal lead/tissue interface, are excluded from
analyses of capture and sensing objectives.
• Pacing capture data lacking required threshold strip doc-
umentation or not measured at 0.5 ms are excluded from
the analysis of the capture threshold objective.
• Patients unable to capture will be assigned a capture
threshold value of 6 V at affected visits for the purpose of
calculating descriptive statistics.
Independent advisory committees
The Investigator will be asked to assess the relationship of
each adverse event to the pacing system, implant proce-
dure and/or the MRI scan. An Adverse Event Advisory
Committee (AEAC) will review the classifications of all
adverse device effects, deaths, technical observations and
adverse events at regular intervals.
A Scan Advisory Committee developed similar MRI scan
protocols for the different MRI machines from the three
manufacturers and assisted in the validation of the indi-
vidual MRI scans. Furthermore, this committee will regu-
larly review the performed MRI scans and determine if the
scan data acquired will be included in the analysis.
The trial is supervised by an independent data monitoring
committee (DMC), consisting of one statistician, one
radiologist and one cardiologist, to review safety data as
well as to review periodically the efficacy data.
Ethical aspects
The study will be conducted according to the investiga-
tional plan, the Declaration of Helsinki concerning medi-
cal research and in accordance with local laws and
regulations of countries where patients are enrolled. Each
center needs Institutional Review Board/Medical Ethics
Committee approval of the study protocol and written
patient informed consent prior to enrolment. Patients
may withdraw from the study at any time without giving
reasons and without jeopardizing their further treatment.
The investigator may also withdraw patients if this is in
their best interests.
Discussion
This study has been designed to confirm the safety and
efficacy of a new pacing system in the MRI environment.
There is much published work on the effects of MRI scans
on patients with implanted devices and recommenda-
tions for minimizing these hazards [4-6,8-15]. The infer-
ence of these reports indicates that dedicated pacing
systems are needed to avoid complications including
arrhythmias, inhibition of pacing output and triggered
stimulations, and RF-related heating of the pacing leads
with potential thermal damage at the electrode/tissue
interface, although there remains some controversy over
this need [3]. Systems designed for safe use in the MR
environment must be considered in the light of a rapidly
increasing number of MR studies being performed world-
wide in all types of patient. Implanted device patients at
present are clearly clinically disadvantaged by being una-
ble safely to undergo MRI in many conditions that they
may develop.
A new system has been designed to address the safety
issues of MRI scanning in patients with implanted devices.
This requires careful clinical assessment, which is the
object of this trial using a randomization technique to
those who will be scanned and a control group who will
not.
In the future, it is hoped, assuming this trial to be success-
ful, that MRI-compatibility may be extended to more
complex devices such as those that deliver cardiac resyn-
chronization therapy and implantable cardioverter defi-
brillators.
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